Table 3.
Impact of disease activity.
| N (P = 70) | Active MCTD(P = 26; 37.1%) |
Quiescent MCTD(P = 44; 62.9%) |
OR | 95%CI | |||
|---|---|---|---|---|---|---|---|
| P | Mean (range) | P | Mean (range) | ||||
| Maternal age (y) | 56 | 16 | 28.8 (17–36) | 40 | 28.5 (18–41) | 0.99 | 0.87–1.13 |
| Disease duration (y) | 56 | 20 | 3.0 (0–9.3) | 36 | 5.8 (0.1–1.13) | 0.80a | 0.65–0.97 |
|
Ratio |
% |
Ratio |
% |
||||
| Good disease controlb | 25 | 5/7 | 71.4 | 15/18 | 83.3 | 0.79 | 0.48–1.32 |
| Steroids/Immunosupp.c | 32 | 4/9 | 44.4 | 10/23 | 43.5 | 1.01 | 0.29–3.52 |
| Preeclampsia | 68 | 5/25 | 20.0 | 7/43 | 16.3 | 0.88 | 0.18–1.23 |
| Caesarean section | 56 | 8/17 | 47.1 | 11/39 | 28.2 | 1.95 | 0.54–7.13 |
| VTE | 70 | 1/26 | 3.8 | 0/44 | 0 | – | – |
| Maternal mortality | 70 | 1/26 | 3.8 | 0/44 | 0 | – | – |
| Prematurity | 46 | 12/15 | 80.0 | 9/31 | 29.0 | 7.60a | 1.93–29.95 |
| IUGR | 43 | 7/16 | 43.8 | 10/29 | 34.5 | 1.48 | 0.04–5.49 |
| NL and CP | 54 | 4/16 | 25.0 | 8/38 | 21.1 | 1.27 | 0.35–4.66 |
| Perinatal mortality | 69 | 11/26 | 42.3 | 1/43 | 2.3 | 16.83a | 1.90–148.7 |
CI: confidence intervals, CP: chondrodysplasia punctata, IUGR: intrauterine growth restriction, N: sample size available, NL: neonatal lupus, OR: odds ratio, P: pregnancy, VTE: venous thromboembolic event.
aStatistically significant on alpha 0.05 threshold.
bSix months prior to pregnancy.
cSteroids or immunosuppressive drugs.